These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 31146509)

  • 1. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
    Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RW;
    Intest Res; 2019 Jul; 17(3):285-310. PubMed ID: 31146509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
    Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RWL;
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1296-1315. PubMed ID: 30848854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.
    Ooi CJ; Makharia GK; Hilmi I; Gibson PR; Fock KM; Ahuja V; Ling KL; Lim WC; Thia KT; Wei SC; Leung WK; Koh PK; Gearry RB; Goh KL; Ouyang Q; Sollano J; Manatsathit S; de Silva HJ; Rerknimitr R; Pisespongsa P; Abu Hassan MR; Sung J; Hibi T; Boey CC; Moran N; Leong RW;
    J Gastroenterol Hepatol; 2016 Jan; 31(1):56-68. PubMed ID: 25819311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1).
    Ooi CJ; Makharia GK; Hilmi I; Gibson PR; Fock KM; Ahuja V; Ling KL; Lim WC; Thia KT; Wei SC; Leung WK; Koh PK; Gearry RB; Goh KL; Ouyang Q; Sollano J; Manatsathit S; de Silva HJ; Rerknimitr R; Pisespongsa P; Abu Hassan MR; Sung J; Hibi T; Boey CC; Moran N; Leong RW;
    J Gastroenterol Hepatol; 2016 Jan; 31(1):45-55. PubMed ID: 25819140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.
    Ran Z; Wu K; Matsuoka K; Jeen YT; Wei SC; Ahuja V; Chen M; Hu PJ; Andoh A; Kim HJ; Yang SK; Watanabe M; Ng SC; Hibi T; Hilmi IN; Suzuki Y; Han DS; Leung WK; Sollano J; Ooi CJ; Qian J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):637-645. PubMed ID: 32672839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):30-36. PubMed ID: 29024102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SURGICAL MANAGEMENT OF ADULT CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS: A CONSENSUS FROM THE BRAZILIAN ORGANIZATION OF CROHN'S DISEASE AND COLITIS (GEDIIB).
    Zabot GP; Cassol OS; Quaresma AB; Gonçalves Filho FA; Baima JP; Imbrizi M; Rolim AS; Carmo AMD; Alves Junior AJT; Santos CHMD; Sobrado Junior CW; Miranda EF; Albuquerque IC; Souza MM; Kaiser Junior RL; Parra RS; Kotze PG; Saad-Hossne R
    Arq Gastroenterol; 2023; 59(suppl 1):1-19. PubMed ID: 36995887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Asia-Pacific consensus on ulcerative colitis.
    Ooi CJ; Fock KM; Makharia GK; Goh KL; Ling KL; Hilmi I; Lim WC; Kelvin T; Gibson PR; Gearry RB; Ouyang Q; Sollano J; Manatsathit S; Rerknimitr R; Wei SC; Leung WK; de Silva HJ; Leong RW;
    J Gastroenterol Hepatol; 2010 Mar; 25(3):453-68. PubMed ID: 20370724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.
    Huynh L; Hass S; Peyrin-Biroulet L; Duh MS; Sipsma H; Cheng M; Lax A; Nag A
    Crohns Colitis 360; 2022 Jan; 4(1):otac001. PubMed ID: 36777550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry.
    Shapiro JM; Zoega H; Shah SA; Bright RM; Mallette M; Moniz H; Grabert SA; Bancroft B; Merrick M; Flowers NT; Samad Z; Lidofsky S; LeLeiko NS; Sands BE
    Inflamm Bowel Dis; 2016 Jun; 22(6):1456-61. PubMed ID: 26926039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.
    Ng SC; Tang W; Ching JY; Wong M; Chow CM; Hui AJ; Wong TC; Leung VK; Tsang SW; Yu HH; Li MF; Ng KK; Kamm MA; Studd C; Bell S; Leong R; de Silva HJ; Kasturiratne A; Mufeena MNF; Ling KL; Ooi CJ; Tan PS; Ong D; Goh KL; Hilmi I; Pisespongsa P; Manatsathit S; Rerknimitr R; Aniwan S; Wang YF; Ouyang Q; Zeng Z; Zhu Z; Chen MH; Hu PJ; Wu K; Wang X; Simadibrata M; Abdullah M; Wu JC; Sung JJY; Chan FKL;
    Gastroenterology; 2013 Jul; 145(1):158-165.e2. PubMed ID: 23583432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    Intest Res; 2018 Jan; 16(1):17-25. PubMed ID: 29422794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    Intest Res; 2018 Jan; 16(1):4-16. PubMed ID: 29422793
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.